How to Cite
Abstract
Interleukin-6 (IL-6) is an inflammatory cytokine which could favor type 2 diabetes development (T2D) by negatively regulating insulin signaling. IL-6 rs1800795 polymorphism has been associated with T2D in several populations and may be involved in its development. The aim was to determine whether the IL-6 rs1800795 (G>C) polymorphism is associated with T2D and related clinical traits.
A case control study was conducted in individuals from a population of Mérida, Yucatán, Mexico, being 198 T2D cases and 162 controls. Anthropometric and biochemical parameters were taken and the rs1800795 polymorphism was genotyped by real-time PCR. Obese men carrying the GC genotype (p=0.036, OR=0.199) and C allele (0.046, OR=0.240) had reduced risk for T2D. Higher levels of systolic blood pressure were observed in diabetic individuals carrying the GG genotype (141.750±25.240) compared to GC carriers (128.769±20.713). A similar result was obtained in an analysis regardless of the diabetes presence. In conclusion rs1800795 polymorphism could be a protective factor for T2D in obese male individuals. The GG genotype was associated with higher blood pressure levels regardless of T2D presence.
References
Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Medical Journal. 2012; 27(4):269-273.
Mendoza-Romo MA, Padrón-Salas A, Cossío-Torres PE, Orozco MS. Prevalencia mundial de la diabetes mellitus tipo 2 y su relación con el índice de desarrollo humano. Rev Panam Salud Publica.2018; 41: e103
Russo MP, Grande-Ratti MF, Burgos MA, Molaro AA, Bonella MB. Prevalencia de diabetes, características epidemiológicas y complicaciones vasculares. Archivos de cardiología de México. 2023; 93(1):30-36.
Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, et al. Prevalencia de prediabetes y diabetes en México: Ensanut 2022. Salud Pública de México. 2023; 65: s163-s168.
Instituto Nacional de Estadística y Geografía. Comunicado de Prensa No.645/21. INEGI; 2021. Consultado 28 de abril de 2023. Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2021/EAP_Diabetes2021.pdf
Bener A, Zirie M, Al-Rikabi, A. Genetics, obesity, and environmental risk factors associated with type 2 diabetes. Croat Med J. 2005; 46(2): 302-307.
Shubrook JH, Chen W, Lim, A. Evidence for the Prevention of Type 2 Diabetes Mellitus. J Am Osteopath Assoc. 2018; 118(11):730-737.
Dendup T, Feng X, Clingan S, Astell-Burt T. Environmental risk factors for developing type 2 diabetes mellitus: a systematic review, Int J Environ Res Public Health. 2018; 15(1):78.
Wiebe JC, Wägner, AM, Novoa-Mogollón FJ. Genética de la diabetes mellitus. Nefrología. 2011; 2(1):111-119.
Sánchez-Pozos K, Menjívar M. Genetic component of type 2 diabetes in a Mexican population. Arch Med Res. 2016; 47(7):496-505.
Laakso M, Fernandes Silva L. Genetics of type 2 diabetes: past, present, and future. Nutrients. 2022; 14(15): 3201.
Domínguez-Cruz MG, Muñoz-Moreno M de L, Totomoch-Serra A, García-Escalante, MG, Burgueño J, Valadez-González N, et al. Pilot genome-wide association study identifying novel risk loci for type 2 diabetes in a Maya population. Gene. 2018; 677:324-331.
Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018; 26(3):685-698.
Plataki MN, Zervou MI, Samonis G, Daraki V, Goulielmos GN, Kofteridis DP. Association of the Interleukin-6 rs1800795 Polymorphism with Type 2 Diabetes Mellitus in the Population of the Island of Crete, Greece. Genet Test Mol Biomarkers. 2018; 22(7), 448-452.
Nadeem A, Naveed, AK, Hussain MM, Aslam M, Siddiqui A, Saeed SA. Variations in association of Interleukin 6 G174C single nucleotide polymorphism with type 2 diabetes mellitus-a review. Int J Diabetes Dev Ctries. 2013; 33(4):186-191.
Cheng H, Zhu W, Zhu M, Sun Y, Sun X, Jia D, et al. Metaanalysis: Interleukin 6 gene174G/C polymorphism associated with type 2 diabetes mellitus and interleukin 6 changes. Journal of cellular and molecular medicine. 2021;25(12): 5628-5639.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35 Suppl. 1:S64–S71pmid:22187472.
Secretaría de Salud. Norma Oficial Mexicana NOM-008-SSA3-2017, Para el tratamiento integral del sobrepeso y la obesidad. México: Diario Oficial de la Federación; 2018. Consultado 19 de mayo de 2019. Disponible en: https://dof.gob.mx/nota_detalle.php?codigo=5523105&fecha=18/05/2018.
Bińkowski J, Miks S. Gene-Calc [Computer software]. 2018. Disponible en: www.gene-calc.pl.
Barberm JA, Thompson, SG. Analysis of cost data in randomized trials: an application of the non parametric bootstrap. Stat Med. 2000; 19(23): 3219-3236.
Dwivedi AK, Mallawaarachchi I, Alvarado LA. Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method. Stat Med. 2017; 36(14): 2187-2205.
Nadeem A, Mumtaz S, Naveed AK, Mansoor Q, Aslam M, Siddiqui, A, et al. Association of IL-6 C-174G (rs 1800795) single nucleotide polymorphism with type 2 diabetes mellitus in Pakistani population. J. Pak. Med. Assoc. 2018; 67: 428-433.de diciembre de 2023. Disponible en: https://doi.org/10.22201/fe.18701442e.2020.35.75511 lights-2021_en.pdf
Saxena M, Agrawal CG, Srivastava N, Banerjee M. Interleukin-6 (IL-6)-597 A/G (rs1800797) &-174 G/C (rs1800795) gene polymorphisms in type 2 diabetes. The Indian J Med Res. 2014; 140(1): 60.
Vozarova B, Fernández-Real JM, Knowler WC, Gallart L, Hanson RL, Gruber JD, et al. The interleukin-6 (− 174) G/C promoter polymorphism is associated with type-2 diabetes mellitus in Native Americans and Caucasians. Hum Genet. 2003;112(4): 409-413.
Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, Wolford JK, et al. IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants’ data from 21 studies. Diabetes. 2006; 55(10): 2915-2921.
Zamora-Ginez I, García-Zapién AG, Flores-Martínez, SE, Sánchez-Corona J. Baez-Duarte BG., Torres-Rasgado, et al. Low prevalence of interleukin-6 haplotypes associated with a decreased risk of type 2 diabetes in Mexican subjects with a family history of type 2 diabetes. Arch Med Res. 2013; 44(7): 529-534.
Lara-Gómez RE, Moreno-Cortes ML, Muñiz-Salazar R, Zenteno-Cuevas R. Association of polymorphisms at− 174 in IL-6, and− 308 and− 238 in TNF-α, in the development of tuberculosis and type 2 diabetes mellitus in the Mexican population. Gene. 2019; 702:1-7.
Khadir A, Tiss A, Kavalakatt S, Behbehani K, Dehbi, M, Elkum, N. (2015). Gender-specific association of oxidative stress and inflammation with cardiovascular risk factors in Arab population. Mediators Inflamm. 2015:512603.
Hayakawa T, Takamura T, Hisada A, Abe T, Nomura G, Kobayashi L. IL-6 gene polymorphism-174G/C does not contribute substantially to hyperlipidaemia and Type II diabetes mellitus in Japanese men. Diabetologia. 2002; 45: 453-454.
Ayele FT, Doumatey A, Huang H, Zhou J, Charles B, Erdos, M. Genome-wide associated loci influencing interleukin (IL)-10, IL-1Ra, and IL-6 levels in African Americans. Immunogenetics. 2012; 64(5): 351-359.
Ghavimi R, Sharifi M, Mohaghegh MA, Mohammadian H, Khadempar, Rezaei H. Lack of association between rs1800795 (-174 G/C) polymorphism in the promoter region of interleukin-6 gene and susceptibility to type 2 diabetes in Isfahan population. Adv Biomed Res. 2016; 5:18.
Hamid YH, Urhammer SA, Jensen DP, Glümer C, Borch-Johnsen K, Jørgensen T, et al. Variation in the interleukin-6 receptor gene associates with type 2 diabetes in Danish whites. Diabetes. 2005; 53(12): 3342-3345.
Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, y Hu FB. Genetic variation in IL6 gene and type 2 diabetes: tagging-SNP haplotype analysis in large-scale case–control study and meta-analysis. Hum Mol Genet. 2006; 15(11): 1914-1920
Kubaszek A, Pihlajamäki J, Komarovski V, Lindi V, Lindström J, Eriksson, J, et al. Promoter polymorphisms of the TNF-α (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 2003; 52(7):1872-1876.
Möhlig M., Boeing H, Spranger J, Osterhoff M, Kroke A, Fisher EVA, el al. Body mass index and C-174G interleukin-6 promoter polymorphism interact in predicting type 2 diabetes. J Clin Endocrinol Metab. 2004; 89(4): 1885-1890.
Humphries SE, Luong LA, Ogg MS, Hawe E, Miller, GJ. The interleukin-6− 174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2011; 22(24): 2243-2252.
Elsaid A, Abdel-Aziz AF, Elmougy R, Elwaseef. Association of polymorphisms G (–174) C in IL-6 gene and G (–1082) A in IL-10 gene with traditional cardiovascular risk factors in patients with coronary artery disease. Indian J Biochem Biophy.
; 51: 282-292.
Jeng JR, Wang JH, Liu WS, Chen SP, Chen MYC, Wu MH, et al. Association of interleukin-6 gene G-174C polymorphism and plasma plasminogen activator inhibitor-1 level in Chinese patients with and without hypertension. Am J Hypertens. 2005;18(4): 517-522.
Ma H, Sun G, Wang W, Zhou Y, Liu D, Tong, Y, et al. Association between interleukin-6-572 C> G and 174 G> C polymorphisms and hypertension: a meta-analysis of case-control studies. Medicine. 2016; 95(2): e2416.
Goyenechea E, Parra MD, Martínez-Hernández JA. Implicación de la IL-6 y su polimorfismo-174G> C en el control del peso corporal y en las complicaciones metabólicas asociadas a la obesidad. An Sist Sanit Navar. 2005; 28(3): 357-366.
Laishram V, Lamabam C, Laikangbam S, Dubey A, Longkumer C, Sharma S, et al. Interleukin-6 in obese type II diabetes with hypertension. Int J Res Med Sci. 2016; 4:896-901.
Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell, J, et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001; 86(3): 1154-1159.
##plugins.facebook.comentarios##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2024 Dr. Nicolás Fragoso-Bargas, Dra. Nina Valadez-González, M.I.S. Lorena Ruiz- García, Dra. Ligia Vera-Gamboa, Dr. Víctor Martínez-Aguilar, Dra. Yumi Nakazawa-Ueji, Dr. Guillermo Valencia-Pacheco